Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 19/20 | 0.55 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10483943 | 0.81 | FDPS (0.73) | FDPSPDE3A | |
| SCHEMBL2453556 | 0.81 | FDPS (0.39) | FDPS | |
| SCHEMBL8588296 | 0.80 | FDPS (0.60) | FDPSGGPS1PDE3A | |
| SCHEMBL15013797 | 0.76 | HTR1A (0.47) | — | |
| SCHEMBL2598121 | 0.75 | FDPS (0.42) | FDPS | |
| SCHEMBL8587034 | 0.71 | FDPS (0.51) | FDPSGGPS1PDE3A | |
| SCHEMBL23521586 | 0.71 | CA12 (0.41) | — | |
| SCHEMBL15452862 | 0.70 | FDPS (0.76) | FDPSGGPS1PDE3A | |
| SCHEMBL4994160 | 0.69 | ALDH1A1 (0.62) | — | |
| SCHEMBL5252015 | 0.69 | CA2 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-4876248-A | Anti-inflammatory products derived from methylene-diphosphonic acid, and process for their preparation | SANOFI (FR) | 1989-10-24 | — | — | US | disclosed |
| US-4746654-A | ANTIARTHRITIC | SANOFI (FR) | 1988-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | FDPS 2668/4885GGPS1 2599/4885PDE3A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.